Fig. 3

Validation of osteogenic performance of BMSCs on scaffold surfaces. (A) ALP staining of the BMSCs on day 14 and Alizarin red staining of the BMSCs on day 21. (B) Quantitative analysis of calcium nodules. (C–E) Relative RUNX-2, ALP, and OCN mRNA expression in BMSCs on days 7 and 14 (n = 3)